Courtney Marabella | Authors


Trastuzumab Deruxtecan Sensitivity Associated With Various Levels of HER2-Expressing Gastric Cancer Cells

April 10, 2021

Trastuzumab deruxtecan has not only demonstrated efficacy as a potential anti-HER2 therapeutic option for patients with HER2-amplified gastric cancers, but has also shown promise in those with HER2 moderate-, low-, and non-expressing disease.

Trial in Progress: NeoADAURA Will Examine Neoadjuvant Osimertinib in Resectable EGFR+ NSCLC

January 31, 2021

The phase 3 NeoADAURA trial will examine both single-agent osimertinib as well as the combination with platinum-based chemotherapy versus chemotherapy alone in the neoadjuvant setting in patients with resectable, stage II to IIIB non–small cell lung cancer whose tumors harbor EGFR mutations.